Literature DB >> 31933469

Applications of Recombinant Monoclonal Antibodies against Filarial Antigen Proteins.

Anizah Rahumatullah1, Muhammad Hafiznur Yunus1, Gee Jun Tye1, Rahmah Noordin1.   

Abstract

This study investigated the applications of recombinant monoclonal antibodies (rmAbs) produced against two recombinant filarial proteins of diagnostic value. Ab5B and Ab3A were produced against recombinant BmSXP, and Ab4 and Ab4-fragment crystallizable (Fc) against recombinant BmR1. Ab5B and Ab4-Fc were found to be useful as quality control (QC) reagents for two commercial rapid test kits, such as Brugia RapidTM and BLF Rapid® (Reszon Diagnostics International Sdn. Bhd., 47600 Subang Jaya, Selangor, Malaysia), respectively. The two rmAbs reacted positively with the corresponding recombinant proteins lined on the nitrocellulose strips of the cassette tests, thus may replace or reduce the need for patient serum samples as positive controls for QC of the commercial kits. They were also successfully conjugated to gold nanoparticles and reacted positively with the test lines containing the corresponding recombinant proteins when directly applied to the cassette tests. The gold-conjugated reagents can be used to confirm the antigenicity of test lines after the storage of the rapid tests for a prolonged period or under unfavorable conditions. Furthermore, Ab5B and Ab3A were shown to be able to capture the target recombinant proteins through immunoaffinity purification, enabling their use for applications that need very highly purified proteins. In conclusion, this study demonstrated several potential uses of rmAb proteins produced against recombinant filarial proteins.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31933469      PMCID: PMC7056413          DOI: 10.4269/ajtmh.19-0777

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  19 in total

1.  Coupling antibody to cyanogen bromide-activated sepharose.

Authors:  Jennifer M Kavran; Daniel J Leahy
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

2.  Computational docking of antibody-antigen complexes, opportunities and pitfalls illustrated by influenza hemagglutinin.

Authors:  Mattia Pedotti; Luca Simonelli; Elsa Livoti; Luca Varani
Journal:  Int J Mol Sci       Date:  2011-01-05       Impact factor: 5.923

3.  Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease.

Authors:  K D Ramaiah; Eric A Ottesen
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

4.  Five computational developability guidelines for therapeutic antibody profiling.

Authors:  Matthew I J Raybould; Claire Marks; Konrad Krawczyk; Bruck Taddese; Jaroslaw Nowak; Alan P Lewis; Alexander Bujotzek; Jiye Shi; Charlotte M Deane
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-14       Impact factor: 11.205

5.  Laboratory Evaluation of a Rapid IgG4 Antibody Test (BLF Rapid™) for Bancroftian Filariasis.

Authors:  Rahmah Noordin; Muhammad Hafiznur Yunus; Keri Robinson; Kimberly Y Won; Subash Babu; Peter U Fischer; Shamilah Hisam; Rohela Mahmud
Journal:  Am J Trop Med Hyg       Date:  2018-12       Impact factor: 3.707

6.  Expression of single-chain variable fragments fused with the Fc-region of rabbit IgG in Leishmania tarentolae.

Authors:  Mathias Lindh Jørgensen; Niels Anton Friis; Jesper Just; Peder Madsen; Steen Vang Petersen; Peter Kristensen
Journal:  Microb Cell Fact       Date:  2014-01-15       Impact factor: 5.328

7.  Global programme to eliminate lymphatic filariasis: the processes underlying programme success.

Authors:  Kazuyo Ichimori; Jonathan D King; Dirk Engels; Aya Yajima; Alexei Mikhailov; Patrick Lammie; Eric A Ottesen
Journal:  PLoS Negl Trop Dis       Date:  2014-12-11

8.  Development and identification of fully human scFv-Fcs against Staphylococcus aureus.

Authors:  Siji Nian; Tong Wu; Yingchun Ye; Xu Wang; Wenfeng Xu; Qing Yuan
Journal:  BMC Immunol       Date:  2016-04-29       Impact factor: 3.615

9.  Antibody-Based Protective Immunity against Helminth Infections: Antibody Phage Display Derived Antibodies against BmR1 Antigen.

Authors:  Anizah Rahumatullah; Izzati Zahidah Abdul Karim; Rahmah Noordin; Theam Soon Lim
Journal:  Int J Mol Sci       Date:  2017-11-22       Impact factor: 5.923

10.  Investment Success in Public Health: An Analysis of the Cost-Effectiveness and Cost-Benefit of the Global Programme to Eliminate Lymphatic Filariasis.

Authors:  Hugo C Turner; Alison A Bettis; Brian K Chu; Deborah A McFarland; Pamela J Hooper; Sunny D Mante; Christopher Fitzpatrick; Mark H Bradley
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.